Steinhorst Nils Alexander, Spitzer Martin, Skevas Christos
Department of Ophthalmology, University Medical Center Hamburg-Eppendorf, Hamburg, Germany.
GMS Ophthalmol Cases. 2020 Aug 6;10:Doc33. doi: 10.3205/oc000160. eCollection 2020.
To report the effects of a single intravitreous injection of bevacizumab for the treatment of secondary choroideal neovascularisation due to large optic disc drusen. A 14-year-old female patient with painless loss of vision in one eye presented with unusually large optic disc drusen and juxtapapillary choroidal neovascularisation with subretinal hemorrhage. She was treated with a single intravitreous injection of bevacizumab. Visual acuity increased from 20/100 to 20/25 within 4 weeks after injection and remained at this level during the 12-month follow-up period. Bevacizumab is a possible primary treatment option for secondary choroidal neovascularisation due to large optic disc drusen in children as an alternative to other more invasive or complex procedures.
报告单次玻璃体内注射贝伐单抗治疗因巨大视盘玻璃膜疣所致继发性脉络膜新生血管的疗效。一名14岁女性患者，单眼无痛性视力丧失，伴有异常巨大的视盘玻璃膜疣和视乳头旁脉络膜新生血管及视网膜下出血。她接受了单次玻璃体内注射贝伐单抗治疗。注射后4周内视力从20/100提高到20/25，并在12个月的随访期内维持在该水平。对于儿童因巨大视盘玻璃膜疣所致继发性脉络膜新生血管，贝伐单抗是一种可能的主要治疗选择，可替代其他更具侵入性或复杂的手术。
